Skip to main content
padlock icon - secure page this page is secure

Review article: comparative pharmacodynamic review of rabeprazole – focus on day 1 data

Buy Article:

$52.00 + tax (Refund Policy)


Proton pump inhibitors have become the preferred therapy for gastro-oesophageal reflux disease and other acid-related disorders. Without clear-cut clinical data to help clinicians differentiate the impact of the five currently available proton pump inhibitors on early symptom relief and health-related quality of life, we can explore potentially relevant differences in pharmacodynamic profiles of these proton pump inhibitors.

In general, rabeprazole 10 and 20 mg achieve greater gastric pH >4 and >3 holding times and area under gastric pH–time curves on day 1 of treatment compared with other proton pump inhibitors.

Superiority in day 1 pharmacodynamic measures corroborates fast antisecretory onset, and supports the premise that rabeprazole will be especially suitable for on-demand use. In particular, comparisons with omeprazole and esomeprazole suggest better day 1 nocturnal acid control with rabeprazole.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: University of Oklahoma College of Medicine, Department of Gastroenterology, Oklahoma City, OK 2: Rutgers College of Pharmacy, Department of Pharmacy Practice, Piscataway, NJ, USA

Publication date: July 1, 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more